BEACON Study: Encorafenib, Binimetinib, and Cetuximab in BRAF-Mutant mCRC

Opinion
Video

Daniel Ahn, DO, describes the BEACON study, a randomized phase 3 trial in metastatic colorectal cancer that led to the FDA approval of a doublet regimen.

Recent Videos
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
5 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content